Vivo Capital, LLC Unicycive Therapeutics, Inc. Transaction History
Vivo Capital, LLC
- $368 Million
- Q1 2025
A detailed history of Vivo Capital, LLC transactions in Unicycive Therapeutics, Inc. stock. As of the latest transaction made, Vivo Capital, LLC holds 11,370,152 shares of UNCY stock, worth $77.3 Million. This represents 1.76% of its overall portfolio holdings.
Number of Shares
11,370,152
Previous 9,970,152
14.04%
Holding current value
$77.3 Million
Previous $7.88 Million
17.72%
% of portfolio
1.76%
Previous 1.54%
Shares
4 transactions
Others Institutions Holding UNCY
# of Institutions
31Shares Held
59.9MCall Options Held
0Put Options Held
0-
Great Point Partners LLC Greenwich, CT11MShares$74.7 Million3.87% of portfolio
-
Octagon Capital Advisors LP New York, NY10MShares$68 Million1.9% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT9.39MShares$63.9 Million0.24% of portfolio
-
Logos Global Management LP San Francisco, CA5.08MShares$34.5 Million0.56% of portfolio
-
Walleye Capital LLC Plymouth, MN4.09MShares$27.8 Million0.01% of portfolio
About Unicycive Therapeutics, Inc.
- Ticker UNCY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,052,500
- Market Cap $102M
- Description
- Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...